Drug intelligence / Profile preview

ADGN 123

Development stage: Preclinical
Lead developer: Aanastra
Modality: MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Peptides, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Parenteral

Overview

ADGN 123 is an investigational antineoplastic drug developed by Aanastra. It is classified as an oligonucleotide, peptide, and RNA-based therapeutic. Its mechanism of action involves inhibiting KRAS protein expression. The drug is currently in preclinical development for cancer, with preclinical trials in the USA utilizing a parenteral route of administration. Pharmacodynamics and adverse event data from these preclinical trials were presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024) in April 2024.

Targets

KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)Tumor-associated cell surface receptors recognized by PEP-NP™ peptides

Beyond the preview

Go deeper on ADGN 123.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADGN 123.

Explore the full profile